Celularity Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Celularity Inc. (CELU) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-04-30
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-12-31 was -$488.00K, a 106.59% decline year-over-year.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-09-30 was $0.00.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-06-30 was $6.00K, a 99.89% decline year-over-year.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-03-31 was $482.00K, a 1277.14% increase year-over-year.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $8.00K.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $8.00M, a 170.26% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-04-30 | |||
| 2024-12-31 | $8.00K 10-K · filed 2026-04-30 | |||
| 2023-12-31 | -$488.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | -$488.00K derived: sum of 2 quarters · filed 2025-05-08 | -$482.00K derived: sum of 3 quarters · filed 2025-05-08 | $0.00 10-K · filed 2025-05-08 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | $6.00K derived: sum of 2 quarters · filed 2024-01-03 | $488.00K 10-Q · filed 2024-01-03 | $7.90M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $488.00K 10-Q · filed 2023-08-14 | $7.90M derived: sum of 3 quarters · filed 2024-07-30 | $3.13M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-03-31 | $482.00K 10-Q · filed 2023-05-22 | $7.89M derived: sum of 2 quarters · filed 2024-07-30 | $3.12M derived: sum of 3 quarters · filed 2024-07-30 | $8.44M derived: sum of 4 quarters · filed 2024-07-30 |
| 2022-12-31 | $7.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $2.64M derived: sum of 2 quarters · filed 2024-07-30 | $7.96M derived: sum of 3 quarters · filed 2024-07-30 | $8.00M 10-K · filed 2024-07-30 |
| 2022-09-30 | -$4.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $552.00K derived: sum of 2 quarters · filed 2022-11-10 | $587.00K 10-Q · filed 2022-11-10 | $376.00K derived: sum of 4 quarters · filed 2023-03-31 |
| 2022-06-30 | $5.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $5.36M 10-Q · filed 2022-08-09 | $5.15M derived: sum of 3 quarters · filed 2023-03-31 | |
| 2022-03-31 | $35.00K 10-Q · filed 2022-05-16 | -$176.00K derived: sum of 2 quarters · filed 2023-03-31 | ||
| 2021-12-31 | -$211.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.96M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $3.17M 10-Q · filed 2021-11-12 | |||
| 2020-12-31 | $671.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |